Background: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed.
Introduction
The increased prevalence of low bone mineral density (BMD) among HIV-infected individuals provides us with the opportunity to study the effect of antiretroviral drugs on bone loss. PIs were recently associated with accelerated loss of BMD resulting from enhanced osteoclast activity in HIV-infected individuals. [1] [2] [3] [4] [5] [6] [7] [8] In the first published study to compare PIs (atazanavir/ritonavir or darunavir/ritonavir) with integrase inhibitors in antiretroviral-naive patients, Brown et al. 3 recorded higher bone loss with both PIs than with the first-generation integrase inhibitor raltegravir. 3 However, it should be considered that all patients were also receiving tenofovir/ emtricitabine, whose pharmacokinetic interaction with PIs could accentuate bone damage associated with tenofovir. Likewise, in the first study to assess a switching strategy, Curran et al. 9 reported results that suggested an improvement in BMD after switching from PIs to raltegravir, maintaining the same nucleosides. 9 More recently, a study on switching from tenofovir/emtricitabine plus a V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
ritonavir-boosted PI to raltegravir plus nevirapine also demonstrated an increase in BMD and a reduction in serum markers of bone turnover after 48 weeks. 10 However, no further data on the impact of withdrawal of PI on bone loss have been published.
The recently marketed second-generation integrase inhibitor dolutegravir has demonstrated better virological and immunological outcomes in antiretroviral-naive subjects than efavirenz (SINGLE study) 11 and darunavir (FLAMINGO study). 12 It is also active against HIV strains resistant to the first-generation agents raltegravir and elvitegravir in heavily treatment-experienced patients (VIKING study).
13 Dolutegravir proved to be safe and well tolerated in all these studies. [11] [12] [13] It is administered once daily without boosting or food requirements and has a long halflife. [14] [15] [16] Its comfortable posology, pharmacokinetics and antiviral potency make dolutegravir a good candidate for a simplification regimen. However, there are only first data that confirm the efficacy of switching from a PI, an NNRTI or an integrase inhibitor to dolutegravir in virologically suppressed, treatment-experienced HIV-infected persons. 17 In addition, published data on the effect of dolutegravir on bone are very scarce; increases in bone turnover markers observed over 144 weeks were significantly lower in ART-naive patients who received dolutegravir plus abacavir/lamivudine than in those who received efavirenz/emtricitabine/tenofovir disoproxil fumarate (SINGLE study). 18 However, changes in BMD have not yet been assessed.
Given the possibility that ritonavir-boosted PIs induce a decrease in BMD, whereas dolutegravir has a neutral effect on bone, we hypothesized that switching from a PI to dolutegravir will improve bone mineralization.
Methods

Study design and patients
We performed a multicentre, active-controlled, randomized, open-label, clinical trial to assess the impact on BMD of switching from a ritonavirboosted PI to dolutegravir. We also assessed the efficacy and safety of dolutegravir in patients with osteopenia or osteoporosis receiving a ritonavir-boosted PI-containing regimen.
Patients from three teaching hospitals in Spain (Barcelona and Madrid) were invited to participate in the study. Candidates were HIV-infected adults who had been receiving a stable antiretroviral combination including abacavir/lamivudine (Kivexa V R ) plus a ritonavir-boosted PI for at least 6 months. In addition, patients had to have maintained undetectable plasma HIV-1 RNA (viral load <50 copies/mL) for at least 12 months and have a lumbar (L2-L4) and/or femoral (trochanter, femoral neck or total neck) T-score -1 on DXA scan (previous 6 months). The exclusion criteria were suspected or documented resistance to integrase inhibitors or NRTIs, secondary causes of osteoporosis except vitamin D deficit (e.g. testosterone deficit and thyroid disease) and therapy with bisphosphonates within the previous 6 months.
Patients were randomly assigned in a 1:1 ratio to switch from PI to dolutegravir 50 mg plus co-formulated lamivudine/abacavir (Kivexa V R ) every 24 h (DOLU group) or to continue with their previous ritonavir-boosted PI plus Kivexa V R (PI group). All patients were followed up for 48 weeks, with visits at baseline and at weeks 4, 12, 24, 36 and 48.
Ethics
All participants signed an informed consent document, and the local ethics committees and health authorities approved the trial (Clinical Trials: NCT02577042).
Study objectives and endpoints
The primary objective of the study was to evaluate the effect on BMD of switching from a ritonavir-boosted PI to dolutegravir in HIV-infected patients with osteopenia or osteoporosis. Therefore, the percentage change in BMD in the lumbar spine (L1-L4) and femur (femoral neck, trochanter and total femur) from baseline to week 48 was measured using DXA and compared between the groups. Bone resorption and formation markers [bone alkaline phosphatase, osteocalcin and N-terminal telopeptide (NTX)] were also compared between the groups at week 48.
The secondary objective was to assess the antiviral efficacy of the switch by comparing: (i) the percentage of patients who maintained virological suppression at week 48 (virological failure was defined as HIV RNA >50 copies in two determinations within 1 month of each other), as assessed using snapshot analysis (ITT), missing data or compliance equal to failure (M-D/C ¼ F); and (ii) CD4! and CD8! T lymphocyte counts at week 48.
The tolerability and safety of the switch were evaluated based on the percentage of patients who withdrew from the study because of toxicity and by comparing laboratory parameters [total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glomerular filtration rate (CKD EPI equation), creatinine, albumin/creatinine ratio and protein/creatinine] between the groups at week 48.
Statistical analysis
The study sample size was calculated using the only available information about the switch to integrase inhibitor from the PIs. 9 We assumed a symmetrical and normal behaviour on the BMD parameters, and took the central value as the median change from baseline reported in Curran et al. 9 The power to detect differences in BMD changes between groups was 83.76%, using a common SD of 0.02 and a power of 87.11%.
The patients' characteristics were described using the median (IQR) for continuous, non-normally distributed variables and percentages for categorical variables. The analysis included comparisons between baseline and week 48 in each group and comparisons between groups (PI versus DOLU) at each visit. Medians were compared using the Mann-Whitney test. The Wilcoxon signed rank test was used to assess the significance of the changes observed over time. The v 2 test or Fisher exact test was used as appropriate to compare discrete variables.
Statistical significance was set at P < 0.05. Statistical analyses were performed using SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Seventy-five subjects were screened; two of them were excluded because they do not fulfil the inclusion criteria (one of them was receiving alendronate treatment for osteoporosis and the other was receiving raltegravir).
The study population comprised 73 patients, of whom 37 were in the DOLU group and 36 in the PI group. The epidemiological and HIV-related characteristics of the patients were well balanced at baseline (Table 1) .
One patient from the DOLU group (2.7%) and three patients in the PI group (8.3%) withdrew from the study early.
BMD, turnover markers and body fat mass
No significant intragroup differences were recorded in either group between baseline and week 48 BMD values for the femoral neck, trochanter, total femur and lumbar spine. No differences were recorded between the groups with regard to the percentage of change from baseline to week 48, although a trend toward Figure 1 ).
Lumbar spine BMD improved by >1% in 56.8% of patients in the DOLU group and in only 33.3% in the PI group: 40% (4 of 10) of those who improved by >1% switched from atazanavir/ritonavir to dolutegravir; 55% (11 of 20) switched from darunavir/ritonavir (800/100 mg) to dolutegravir; 83% (5 of 6) switched from lopinavir/ritonavir to dolutegravir; and 100% (1 of 1) switched from fosamprenavir/ritonavir to dolutegravir. No significant differences in bone turnover markers were recorded in any group between baseline and week 48 values of bone resorption and formation markers (bone alkaline phosphatase, osteocalcin and NTX). Similarly, no differences were seen between the groups with regard to these parameters at week 48 (Table 3) .
No intragroup differences were seen in trunk fat from baseline to week 48 (P ¼ 0.237 in the PI group and P ¼ 0.520 in the DOLU group). No differences were seen between the DOLU and PI groups with respect to changes from baseline to week 48 in trunk fat (P ¼ 0.552) and total fat (P ¼ 0.925). CD4! and CD8! T lymphocyte counts did not change significantly from baseline to week 48 in any group, and no differences were observed between the DOLU and PI at week 48 (Table 4) .
Antiviral efficacy
Tolerability and safety
Significant differences between the groups were seen at week 48 for the following parameters: (i) total cholesterol (lower in the DOLU group, P ¼ 0.009); (ii) HDL cholesterol (higher in the DOLU group, P ¼ 0.027); (iii) triglycerides (lower in the DOLU group, P < 0.001); (iv) creatinine (higher in the DOLU group, P ¼ 0.022); and (v) renal glomerular filtrate rate by CKD EPI equation (lower in the DOLU group, P ¼ 0.048) ( Table 4) . Values for the remaining parameters studied remained stable, with no differences between the groups at week 48 (Table 4) .
One patient (2.7%) from the DOLU group withdrew from the study (voluntarily) at week 24. In the PI group, three patients (8.3%) withdrew [two lost to follow-up at week 12 and one due to nephrolithiasis and rupture of the ureter at week 36 (neither associated with the study drug)]. Two patients from the DOLU group reported study drug-related adverse events (grade 1 anxiety and grade 1 nausea) a few days after initiation of dolutegravir. The adverse events did not lead to interruption of treatment and vanished in weeks.
Discussion
Simplification from a ritonavir-boosted PI to dolutegravir plus fixed-dose abacavir/lamivudine (Kivexa V R ) maintained antiviral efficacy, was well tolerated and improved the lipid profile. However, no significant increase in BMD was observed 48 weeks after switching although a trend toward improvement was seen in the lumbar spine.
Bone loss in antiretroviral-naive patients who start therapy with the integrase inhibitor raltegravir was lower than in patients receiving the ritonavir-boosted PIs atazanavir or darunavir 3 or tenofovir. 19 Similarly, an improvement in BMD was observed when the PI or tenofovir was replaced by raltegravir. 9, 10 These data lead us to expect a beneficial effect of integrase inhibitors on BMD, although no data are available for dolutegravir.
In our study, the switch from a ritonavir-boosted PI to dolutegravir while maintaining Kivexa V R in patients with low BMD did not lead to a statistically significant improvement in lumbar and femoral BMD, and bone turnover markers did not vary after 48 weeks. These unexpected results could be explained by the following observations: (i) PIs are less deleterious for bone than we expected and probably less than tenofovir (it is equally likely that PIs have no direct effect on BMD and rather changes observed in BMD with PIs Negredo et al.
resulted from the effect of PIs on tenofovir concentrations, due to the pharmacokinetic interactions between these drugs); (ii) the bone loss initially attributed to the PI is not class-effect toxicity for all PIs (our participants mainly received darunavir); and/or (iii) switching to dolutegravir is not beneficial. Another possible explanation is that including only patients with tenofovir-sparing regimens masked the full extent of the damage that boosted PIs can do to bone and, at the same time, minimized the benefit of switching from boosted PI to dolutegravir. Considering these reasons, more studies are needed, with a longer follow-up (at least 2 years); data that emerged from previous studies of our group showed improvements in trochanter BMD were obtained after 2 years of different interventions. 20, 21 However, although no statistically significant differences between the groups were recorded, lumbar spine BMD improved by 1.43% (baseline to week 48) in patients who switched to dolutegravir, while the PI group remained stable (0.12%). This improvement is present despite the lack of changes in abdominal fat, and is similar to that observed in a previous study involving a switch from a PI to raltegravir. 9 In contrast, femoral neck, trochanter and total femur BMD did not show relevant variations for any treatment. These data could point to an incipient improvement in BMD in the lumbar spine, a region in which improvement is usually earlier and more rapid than in the hip. Lumbar BMD improved by >1% after the switch in all but one patient who interrupted lopinavir/ritonavir (83%), suggesting that interruption of higher doses of ritonavir could have a beneficial effect on bone remineralization. 8 Further studies with larger samples and longer follow-ups are necessary if these issues are to be resolved.
Independently of the results for bone, antiviral efficacy was similar for dolutegravir and the PIs. To our knowledge, these are the first data at week 48 from a randomized study in which dolutegravir is compared head to head with PIs in virologically suppressed HIV-infected patients. Dolutegravir has proven superior to efavirenz and ritonavir-boosted darunavir and non-inferior to raltegravir in antiretroviral-naive patients. 11, 12, 22, 23 It also proved From PIs to dolutegravir JAC superior to raltegravir in a study with antiretroviral-experienced patients who experienced virological failure. 24 Nonetheless, no data are available on dolutegravir as a simplification approach in patients receiving PIs. The only preliminary data are those that were recently reported at week 24 by Trottier et al. 17 who demonstrated similar efficacy between the dolutegravir-based regimen and the PI-based one. Our data support the use of dolutegravir in combination with Kivexa V R (currently available as a single-tablet regimen, Triumeq V R ) as a new and effective simplification option for virologically suppressed HIV-1-infected individuals.
In our study, the combination dolutegravir plus Kivexa V R was well tolerated, and no study drug-related interruptions were recorded. The combination was a simple regimen, which is currently available as a single tablet (Triumeq V R ), thus making it a very attractive simplification regimen with very few drug-drug interactions. In addition, the switch from a PI to dolutegravir led to an improvement in lipid profile, even when most patients were receiving the PIs with the best lipid profile (i.e. darunavir and atazanavir). The beneficial changes in lipid values had already been seen in the initial studies with dolutegravir, which was compared with ritonavir-boosted darunavir. 12 Given the effect of dolutegravir on creatinine secretion, we observed a small increase in serum creatinine and a decrease in estimated renal glomerular filtrate rate among participants who started dolutegravir. However, this change is not clinically significant, since it is well known that it does not reflect changes in the actual glomerular filtration rate.
11
In conclusion, the combination dolutegravir plus Kivexa V R (currently Triumeq V R ) seems to be an attractive simplification strategy for virologically suppressed HIV-infected individuals receiving a ritonavir-boosted PI-based regimen. Antiviral efficacy was similar to that of the PI regimen, and tolerability was good, toxicity low and the lipid profile improved. Although no significant changes in BMD were observed, an incipient improvement in the lumbar spine BMD was seen in patients who switched to dolutegravir. Longer studies are necessary to assess this issue, before the beneficial effects of interrupting PI therapy on bone can be recommended.
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